Tas-109

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

TAS-109 is an experimental medication currently being studied in clinical trials for advanced colorectal cancer. It is being investigated to see if it can slow the growth or spread of the cancer (progression-free survival) and to assess its overall effectiveness (antitumor activity, objective tumor response, duration of clinical benefit, overall survival) and safety. The trial is designed to evaluate how TAS-109 works in patients with advanced colorectal cancer. It is not yet approved for use in colorectal cancer.

Mechanism of Action

The specific way TAS-109 works (its mechanism of action) is being studied in clinical trials. It is designed to target processes involved in cancer cell growth and survival.

Side Effects

Side effects are still being evaluated in ongoing clinical trials. The safety profile of TAS-109 is one of the key aspects being assessed in the clinical trials.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT00824161 Phase 2
Archived
Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
United States

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
781 trials
Leucovorin
Other Medications
641 trials
Paclitaxel
Other Medications
54 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Trifluridine
Other Medications
48 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.